Excessive Gingival Display
Conditions
Keywords
gummy smile, Botulinum toxin type A, excessive gingival display
Brief summary
It has been noted since the start of using botulinum toxin for both medical and cosmetic indications that some patients simply don't achieve the responses to the drug that others do, leading to increased dose requirements and more frequent treatments. It was from this observation that researchers started to look at the zinc levels of patients and consider the concept of supplementation. In a recent systematic review, it was reported that there is very scant evidence to determine the exact clinical effects and duration of BTX-A when injected to treat gummy smile patients. Therefore, the investigators want to administrate of zinc supplements to patients prior to BTX-A injection to study if it will enhance its clinical effects, since it is from the zinc dependent metalloprotease family, where for each botulinum toxin molecule to be effective in paralyzing a muscle response it must be associated with a molecule of zinc which could be found within the cells of the body. Participants with esthetic concern of excessive gingival display who meets the inclusion criteria will be assigned randomly and blindly to one of the 2 groups. Patients in the intervention group will take zinc supplement tablets to increase zinc levels for 4 days before botulinum toxin injections. While patients in the control group will take placebo tablets 4 days prior to the injections. All tablets will be placed in envelopes for blinding the operator, and numbered by a supervisor to allocate patients again in their groups for statistical results. Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women. After 2 weeks the patients would come for an additional touch up dose (1 unit at each injection point).
Interventions
DRUGBotulinum toxin type A
Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015).
DIETARY_SUPPLEMENTZinc supplementation
zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with excessive gingival display \>3mm. * Adults \>18 years. * Non-smokers. * Systemically healthy. * Normal clinical crown dimensions. * Hypermobile lip and Short or mild VME.
Exclusion criteria
* Severe VME. * Pregnant or lactating females. * Patients with inflamed gingiva or gingival enlargement. * Inflammation or infection at the site of injection. * Patients with known allergy to any of the components of BTX-A or BTX-B (i.e. BTX, human albumin, saline, lactose and sodium succinate). * Patients using anticholinesterase or other agents interfering with neuromuscular transmission. * Psychologically unstable or who have questionable motives and unrealistic expectations. * Dependent on intact facial movements and expressions for their livelihood (e.g. actors, singers, musicians and other media personalities). * Afflicted with a neuromuscular disorder (e.g. myasthenia gravis, Eaton-Lambert syndrome).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the amount of gingival display | it will be measured after 2 weeks, then after 6, 12, 18 and 24 weeks | Change in gingival display will be measured using a ruler |
Countries
Egypt
Outcome results
None listed